Targeted Therapy in Non-Small Cell Lung Cancer: Review Article | ||
| The Egyptian Journal of Hospital Medicine | ||
| Article 113, Volume 92, Issue 1, July 2023, Pages 6207-6212 PDF (693.2 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejhm.2023.313892 | ||
| Abstract | ||
| Lung cancer is responsible for the majority of cancer-related deaths in this nation. Based on histological type, the two primary forms of lung cancer are small cell lung cancer (SCLC) (15%) and non-small cell lung cancer (NSCLC) (85%). The genesis of lung cancer is impacted by an assortment of variables, involving cigarette smoking, pollutants in the air, factors related to the environment, workplace cancer-causing agents, nutrition, infections caused by viruses, previous lung disorders, inherited, and immunologic factors. Oftentimes, non-small cell lung cancer does not become apparent until it has advanced. In between 50 and 75% of patients, coughing prevails, subsequent to hemoptysis, chest discomfort, and breathlessness. Laboratory abnormalities or paraneoplastic syndromes are less frequent signs. The most prevalent type of cancer that leads to mortality is lung cancer. Lung cancer occurrence worldwide was estimated at around 1.8 million new cases in 2012, according to the International Agency for Cancer Research (IARC) of the WHO. It is presently being established which therapy is best for persons with lung cancer. Specifically, for those with pulmonary adenocarcinoma, large-cell histology, and non-small-cell lung cancer, it is critical to look for PD-L1 expression levels, EGFR alterations, ALK, and ROS1 translocations. These tests can also be carried out on squamous cell histology patients who have never smoked or smoke seldom. A thorough genomic scan for HER2 insertions, BRAF mutations, MET, TRK, and RET variants could potentially uncover experimental targeted medicines currently undergoing evaluation in human clinical studies in alongside contributing to various other molecular discrepancies. | ||
| Keywords | ||
| Lung cancer; Mortality; SCLC; Non SCLC; EGFR; Review; Sohag University | ||
|
Statistics Article View: 107 PDF Download: 270 |
||
